6 July 2023
This study reports recurrence-free survival and overall survival results for participants with stage III melanoma from the OpACIN and OpACIN-neo trials. Data confirms the high survival rates after neoadjuvant combination checkpoint inhibition in macroscopic stage III melanoma, especially for patients with a pathologic response. Pathologic response is the strongest surrogate marker for long-term outcome.
6 July 2023
This study uses UK mortality rates between 2018 and 2022 to create a life expectancy predictive scoring system for elderly UK populations. This work is intended to support decision-making when considering surgical intervention for BCC in elderly patients.
5 July 2023
This recent review compared sun protection legislation and guidelines in the Group of Seven, Australia and New Zealand. It recommended that countries should legislate sun protective behaviors and infrastructure in schools, childcare, sports and recreation settings, enact stringent sunscreen and UVR-textile manufacturing standards, implement favorable taxation policies for sun protective equipment and over-the-counter products and ban sunbeds.
28 June 2023
This recent study aimed to quantify adult preferences for adjuvant immunotherapy for resected melanoma. The study concludes that almost three-quarters of respondents chose adjuvant immunotherapy over no adjuvant immunotherapy, preferring treatment that improved efficacy and safety. Findings may inform decisions about access to adjuvant immunotherapy following surgery for melanoma.
28 June 2023
According to this recent cohort study of patients with advanced melanoma receiving first-line immune checkpoint inhibitor therapy, treatment-free survival represents a patient-centric, informative end point. The study concludes that patients treated with combination nivolumab-ipilimumab spent more time alive and free from systemic anticancer therapy than those treated with anti–PD-1 monotherapy alone.
28 June 2023
This recent study investigated adjuvantly treated stage III melanoma patients under real-world conditions. It concludes that PD1-treated patients had more and earlier recurrences than targeted therapy (TT) patients. In BRAF-mutated patients adjuvant TT might prevent early recurrences more effectively than PD1 treatment. Management of recurrence despite adjuvant treatment is challenging with low response to current therapeutic options.
28 June 2023
This recent research states that several large multicenter trials have challenged the necessity of complete lymph node dissection, leading to a paradigm shift. While some controversy remains, the standard of care for melanoma is progressing toward a consensus.
28 June 2023
The Auckland Medical Research Foundation (AMRF) is calling for applications for the JI Sutherland Medical Research Fellowship. This Fellowship is open to medical or science graduates with New Zealand residency, permanent residency or citizenship who wish to undertake full-time medical research for a PhD or an MD in the specific field of melanoma or other skin cancer research.
19 June 2023
Authors of this recent study demonstrate the successful use of social media advertising to direct high-risk groups to online health information about indoor tanning. Future research quantifying tanning visits pre- and post- indoor tanning interventions is needed to guide future public health efforts.
18 June 2023
This review may help to develop therapeutic strategies for improving the clinical response rate of PD-1 inhibitors and prolonging the survival of patients by activating mitochondrial function in tumour and T cells.
